newsfilter
← Latest News
Business Wire·

Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14

  • Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), announced Qare™, a comparative health platform developed through the ai² Accelerator™.
  • Qare™ enables users to compare treatment experiences against cohorts of similar patients using different medications within the same therapeutic class.
  • The platform launches initially in the GLP-1 category with a public availability date of October 14, 2026.
  • Qare™ is designed to address gaps in healthcare data by allowing patients to evaluate how their outcomes compare to others facing similar circumstances.
  • CEO Erik Emerson stated the platform aims to shift focus from a $70 billion global analytics market that excludes patient benefits to one centered on patient accountability.
  • Additional drug classes are expected to be added to the platform in future releases.
  • The company selected National GLP-1 Day for the launch to highlight the importance of patient-driven health data.
  • Users can visit qare-app.com for more information ahead of the October 14, 2026 public release.
  • Glucotrack, Inc. operates Lōkahi Therapeutics™ and also focuses on diabetes technologies, including the investigational Glucotrack CBGM system.